ES2132204T3 - Procedimiento de preparacion de antigenos y de vacunas del virus de la hepatitis a (hav). - Google Patents

Procedimiento de preparacion de antigenos y de vacunas del virus de la hepatitis a (hav).

Info

Publication number
ES2132204T3
ES2132204T3 ES93402469T ES93402469T ES2132204T3 ES 2132204 T3 ES2132204 T3 ES 2132204T3 ES 93402469 T ES93402469 T ES 93402469T ES 93402469 T ES93402469 T ES 93402469T ES 2132204 T3 ES2132204 T3 ES 2132204T3
Authority
ES
Spain
Prior art keywords
hav
vaccines
hepatitis
antigens
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93402469T
Other languages
English (en)
Inventor
Bernard Fanget
Alain Francon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Application granted granted Critical
Publication of ES2132204T3 publication Critical patent/ES2132204T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE MULTIPLICA EL VIRUS HAV SOBRE CELULAS COMPETENTES, SE LIZAN LAS CELULAS INFECTADAS, SE RECOGE LO QUE SUBSISTE Y SE PROCEDE A LA PURIFICACION POR UNA OPERACION DE CROMATOGRAFIA SOBRE SOPORTE INTERCAMBIADOR DE ANIONES Y UNA OPERACION DE GEL-FILTRACION, LAS OPERACIONES DE PURIFICACION SON EFECTUADAS EN PRESENCIA DE UN DETERGENTE Y LA OPERACION DE CROMATOGRAFIA ES EFECTUADA EN UNAS CONDICIONES QUE RETIENEN LOS VIRIONES O CAPSIDAS VIRALES QUE SON A CONTINUACION ELEGIDOS.
ES93402469T 1992-10-14 1993-10-07 Procedimiento de preparacion de antigenos y de vacunas del virus de la hepatitis a (hav). Expired - Lifetime ES2132204T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9212285A FR2696748B1 (fr) 1992-10-14 1992-10-14 Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).

Publications (1)

Publication Number Publication Date
ES2132204T3 true ES2132204T3 (es) 1999-08-16

Family

ID=9434534

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93402469T Expired - Lifetime ES2132204T3 (es) 1992-10-14 1993-10-07 Procedimiento de preparacion de antigenos y de vacunas del virus de la hepatitis a (hav).

Country Status (10)

Country Link
US (1) US5731187A (es)
EP (1) EP0593339B1 (es)
JP (1) JP3724821B2 (es)
AT (1) ATE179428T1 (es)
CA (1) CA2108292C (es)
DE (1) DE69324645T2 (es)
DK (1) DK0593339T3 (es)
ES (1) ES2132204T3 (es)
FR (1) FR2696748B1 (es)
GR (1) GR3030636T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018819A1 (en) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification of respiratory syncytial virus antigens
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
ATE477320T1 (de) * 1996-12-13 2010-08-15 Schering Corp Methoden zur virus-reinigung
CA2482512C (en) * 2002-04-30 2011-09-20 Oncolytics Biotech Inc. Improved viral purification methods
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
IL246769B (en) * 2015-07-23 2020-09-30 Grifols Sa Methods for the isolation of a virus produced in a test tube (in vitro) and the clearance of a virus
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
KR102277089B1 (ko) 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스
JP2024004020A (ja) * 2022-06-28 2024-01-16 Ｋｍバイオロジクス株式会社 Ａ型肝炎ウイルスのクロマトグラフィー精製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Also Published As

Publication number Publication date
DE69324645D1 (de) 1999-06-02
EP0593339A1 (fr) 1994-04-20
JP3724821B2 (ja) 2005-12-07
JPH06279317A (ja) 1994-10-04
GR3030636T3 (en) 1999-10-29
US5731187A (en) 1998-03-24
CA2108292C (en) 2005-04-12
EP0593339B1 (fr) 1999-04-28
DK0593339T3 (da) 1999-11-08
FR2696748A1 (fr) 1994-04-15
DE69324645T2 (de) 1999-12-30
CA2108292A1 (en) 1994-04-15
ATE179428T1 (de) 1999-05-15
FR2696748B1 (fr) 1994-12-30

Similar Documents

Publication Publication Date Title
MXPA96005662A (es) Vacunas de papilomavirus.
ES2132204T3 (es) Procedimiento de preparacion de antigenos y de vacunas del virus de la hepatitis a (hav).
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
EP0595436A3 (en) Respiratory and porcine reproductive syndromes virus, vaccines and virol DNA.
ES511668A0 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
PT677114E (pt) Virus da variola suina recombinante
ATE152355T1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
DK643387D0 (da) T-celle-epitoper af hepatitis b-virus-nucleocapsid-protein
PT88178A (pt) Metodo para a purificacao de virus da hepatite a
EA200100236A1 (ru) Способ очистки вирусных частиц, подобных вирусу папилломы человека
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
ATE81357T1 (de) Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein.
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
LU91303I2 (fr) Gallivac HVT IBD- virus vivant recombinant vHVT013-69,au minimum 3,0 log 10 UFP
DE3071225D1 (en) Influenza virus vaccines, process for preparing them and process for propagating influenza viruses
DE69533067D1 (de) Hepatis e-virus antigene und dessen verwendungen
EP1057889A4 (en) IMPROVED IMMUNOGEN FOR INACTIVATED VACCINE AGAINST INFECTION WITH JAPANESE ENCEPHALITIS VIRUSES AND METHOD FOR THE PRODUCTION THEREOF
DK498387D0 (da) Virus-dna-sekvens
Cox The structural proteins of rabies virus
ES2100185T3 (es) Secuencia de adnc y deteccion del virus de la hepatitis c.
FI952778L (fi) Hepatiitti-C-viruksen (HCV) 3-ei-rakenne-peptidejä, vasta-aineita niitä vastaan ja menetelmiä HCV:n toteamiseksi
DK240089D0 (da) Fremgangsmaade til udvinding af et proeveantigen til diagnosticering af infektion med bovint herpesvirus
FI930519A7 (fi) Peptiidejä HIV-viruksen aiheuttaman infektion torjumiseksi sekä menete lmä niiden käyttämiseksi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 593339

Country of ref document: ES